t~ Methods for transiently disrupting the blood-brain barrier (BBB) which are consistent with survival are described for immature Fischer 344 rats weighing 40 to 99 gm. A catheter was retrogradely inserted into the external carotid artery to the level of the bifurcation. Perfusion of 1.4 M mannitol or 1.6 M arabinose, at a rate of 0.01 to 0. i ml/sec for 30 seconds, resulted in transient BBB disruption as measured by Evans blue dye (EBD) staining. Higher flow rates or perfusion with 10% to 30% dimethyl sulfoxide were associated with a mortality rate ranging from 0% to 44%. Perfusion with 0.9% sodium chloride or intrafemoral artery perfusion with 1.4 M mannitol did not disrupt the BBB. Optimum BBB disruption as measured by EBD staining was achieved with 1.6 M arabinose at 0.026 ml/sec for 30 seconds, at which time all of the 42 experimental animals had BBB disruption; all of the animals so treated survived 2 weeks following perfusion. This technique will allow the efficacy of delivering chemotherapeutic agents following BBB disruption to be tested in several of the more commonly used small-animal models for brain-tumor research.
M
ALIGNANT gliomas are invariably fatal, despite treatment with radiation and chemotherapy) The mechanisms of this resistance to therapy are not completely understood, but appear to include both cellular heterogeneity and inadequate drug delivery. Since dose-response curves for cancer chemotherapeutic agents are often steep, and cellular resistance is dose-related, even relatively small increases in delivery of agents may be beneficial. Hence, there has been much recent interest in increasing drug delivery by different routes of administration of chemotherapeutic agents, including intra-arterial delivery with or without prior blood-brain barrier (BBB) disruption. Initial work, however, has not clearly defined the role played by the route of delivery in either achieving optimal drug levels in tumor or in therapeutic efficacy. 1,~ 1,13,15 Thus, further work is required in animal models before human studies can be conducted.
Several of the most commonly used and best defined animal models employ Fischer 344 rats,* including the 9L gliosarcoma model, 2 the avian sarcoma virus (ASV)-induced glioma model, 7'25'26 and the immune-depressed * Fischer rats obtained from Charles River Breeding Laboratories, 251 Ballardvale Street, Wilmington, Massachusetts.
rat model for intracranial transplantation of human tumorsfl 4 For these last two models, the optimum time of therapeutic intervention is 28 to 38 days of age, when rats range in weight from 40 to 99 gm. In the past, this small size has limited the modes of delivery of therapeutic agents to oral, intraperitoneal, intravenous, or, most recently, intracarotid administration. 5 In this study, we have technically adapted the hyperosmolar BBB disruption procedures of RapoporP 9 to 40-to 99-gin rats and have compared various flow rates, infusion durations, and agents. We found that 1.4 M mannitol and 1.6 M arabinose infused for 30 seconds at 0.026 ml/sec were quite effective in achieving transient BBB disruption in these immature rats with insignificant morbidity and mortality rates associated with the procedure. Dimethyl sulfoxide (DMSO), however, was associated with unacceptably high rates of morbidity and mortality.
Materials and Methods
Male Fischer 344 rats, each weighing 40 to 99 gin, were anesthetized with methoxyflurane. Under • 3.5 to • 10 magnification, the fight common carotid, and external and internal carotid arteries were exposed and freed of connective tissue. A polyethylene catheter (PE FIO. 1. A simplified drawing of the rat brain demonstrating the dominant cerebral flow from the anterior and middle cerebral arteries. (Modified from Greene?)
10 + PE 50) with a No. 28 needle attached was then inserted into the external carotid artery and passed proximally to the bifurcation; the bevel was then rotated toward the internal carotid artery and the needle was secured with a silk suture. When the device was positioned properly, blanching of the internal carotid artery was visible following infusion under direct vision. For the intravenous administration of agents, a No. 28 needle, attached to PE 10 tubing filled with 0.9% NaCI and 100 IU/ml Na heparin, was placed in the femoral vein. For serial blood sampling or for systemic hyperosmolar perfusion, a No. 28 needle, attached to PE 10 + PE 50 tubing filled with 0.9% NaC1 and 100 IU/ml Na heparin, was tied into the femoral artery.
Evans blue dye (EBD) was prepared in a filtered 2% solution with 0.9% NaC1, and injected intravenously at 2 ml/kg body weight 5 minutes prior to administration of intracarotid or intrafemoral agents. This quantity of dye binds almost completely to plasma albumin and serves as a qualitative indicator of BBB integrity. 6 '9-21 Transient disruption of the BBB was achieved utilizing a modification of the technique described by Rapoport, et al. 19 "2~ Infusion was performed through the carotid catheter with a constant-flow pump.t For infusion, 1.58 M L(+)-arabinose in 0.9% NaCI, 1.4 M mannitol, DMSO at 10%, 20%, or 30% concentrations, and 0.9% NaC1 were used in different groups of rats. All agents were filtered and administered at 37~ Flow rates were checked for actual delivered volume/time t Constant-flow pump manufactured by Harvard Apparatus Co., Inc., The Ealing Corp., 22 Pleasant Street, South Natick, Massachusetts.
prior to each experiment. Because infusion of the hypertonic solutions and the chemical agents often resulted in transient apnea, it was frequently necessary to assist animal respiration by forced ventilation using a 5-cc syringe attached to a sphigmomanometer pressure bulb.
For evaluation of BBB disruption, animals were killed at 10 minutes by cervical transection. The brain was removed and divided into five sections: the brain stem and cerebellum, the left middle cerebral artery (MCA) distribution, the left anterior cerebral artery (ACA) distribution, the right ACA distribution, and the right MCA distribution (Fig. 1) . The staining of each region by EBD was graded as follows: Grade 0, no staining; Grade 1 +, just noticeable staining; Grade 2+, moderate blue staining; and Grade 3+, dark blue staining 19-21 (Fig. 2) .
Results

Determination of Optimum Flow Rate
Initial evaluation of BBB disruption was conducted with 1.4 M mannitol ( Table 1 ). The degree of staining and the percentage of animals with BBB disruption were calculated only from animals surviving 10 minutes following perfusion. Flow rates ranging from 0.010 to 0.103 ml/sec for 30 seconds were initially studied. At 0.103 ml/sec, variable times of perfusion ranging from 1 to 30 seconds were also evaluated. More than 60% of animals exhibited staining at mannitol flow rates ranging from 0.010 to 0.103 ml/sec when perfused for 30 seconds. With mannitol delivered at 0.103 ml/sec, 20% to 33% of animals demonstrated staining at 1, 3, and 5 seconds of perfusion, while at 10, 20, and 30 seconds 100% of animals had evidence of BBB disruption. Respiratory arrest resulted in 17% to 100% of animals at flow rates greater than 0.17 ml/sec for 30 seconds and at 0.103 ml/sec for 5 to 30 seconds. These respiratory arrests were usually transient and, at the lower flow rates, the animals often did not require ventilatory assistance. At the higher flow rates, respiratory pauses were more prolonged and death was first noted at mannitol infusion rates of 0.052 ml/sec for 30 seconds and 0.103 ml/sec for 20 seconds, despite attempted resuscitation.
In animals weighing 40 to 99 gm, optimum BBB disruption with minimal respiratory difficulty was noted at 0.026 and 0.035 ml/sec for 30 seconds. With these two dose groups, Grade 1 + and 2+ staining was seen in 21 (75%) of 28 animals, and in 12 (60%) of 20 animals, respectively. Intense Grade 3+ staining was frequently noted in animals that died before 10 minutes, and was seldom compatible with survival.
The influence of animal weight on degree of staining and respiratory arrest was also evaluated ( Table 2 ). At flow rates of 0.017, 0.026, and 0.035 ml/sec for 30 seconds, the percentage of animals with BBB disruption tended to be higher in 40-to 69-gm animals than in 70-to 99-gm animals. At flow rates of 0.052 and 0.068 ml/sec this trend was no longer seen. The degree of staining did not directly correlate with animal size. Death immediately following infusion was recorded only at or above a flow rate of 0.052 ml/sec and only among 40-to 69-gm animals.
Comparison o f Agents
We selected a flow rate of 0.026 ml/sec at an infusion duration of 30 seconds as the optimal method for disrupting the BBB with 1.4 M mannitol. We then studied the effects on the BBB of 1.6 M arabinose and 10% to 30% DMSO at this flow rate and infusion (Table 3) . In 42 animals, 1.6 M arabinose disrupted the BBB in 100% of animals, with Grade 2+ staining in 50% of animals. Transient respiratory pauses were seen in all animals, but no deaths occurred.
Dimethyl sulfoxide (DMSO) proved to be unsatisfactory as an agent for disrupting the BBB. At 10% concentration, only seven of 14 animals had any staining with EBD and staining was mild in all cases. At 20% and 30% of DMSO, BBB disruption was achieved in three of 10 and 30 of 32 animals, respectively, but at 10 minutes following infusion 6% and 9% of the animals were dead, despite attempted resuscitation. All animals that received DMSO developed generalized epileptiform shaking. Infusion of 0.9% saline resulted in neither respiratory depression nor BBB disruption in any animals evaluated.
We also compared results obtained with 1.4 M mannitol administered at flow rates of 0.052 ml/sec for 30 seconds to results with 1.6 M arabinose and 0.9% saline given at the same rate by the intracarotid route, and to mannitol infused into the femoral artery (Table 4) . Of 15 animals given intracarotid arabinose, 14 (93%) had BBB disruption and none died; in comparison, only 24 (77%) of 31 animals given intracarotid mannitol had BBB disruption but 11 of the total of 42 rats (27%) died. No evidence of BBB disruption or respiratory depression was seen with either 0.9% intracarotid saline or 1.4 M intrafemoral mannitol. Attempts at intravenous infusion of mannitol at 0.026 and 0.052 ml/sec for 30 seconds consistently resulted in death.
Patterns of Disruption
Patterns of distribution of BBB disruption were evaluated in 185 animals perfused with arabinose, mannitol, or DMSO. The relationship between distribution of staining and intensity of staining was similar in each of the groups, irrespective of the agent employed. In 29 (16%) of the 185 animals, staining was limited to the ipsilateral MCA distribution, 73 (39%) had staining in the ipsilateral MCA and ACA distribution, 80 (43%) had staining in the ipsilateral hemisphere and the contralateral ACA territories, and three (2%) had diffuse staining in both hemispheres. In 103 animals with Grade 1 + staining, 29 (28%) had staining in the ipsilateral MCA distribution alone, 54 (52%) had staining in the ipsilateral hemisphere in both ACA and MCA territories, and 20 (19%) had staining which extended to include the contralateral ACA area. In 71 animals with Grade 2+ staining, none had staining limited to the ipsilateral MCA territory, 18 (25%) had staining in the ipsilateral ACA and MCA areas, 52 (73%) had staining which involved the ipsilateral hemisphere and the contralateral ACA area, and one (1%) had staining in all four areas. Of 11 animals with Grade 3+ staining, none had staining solely in the ipsilateral MCA territory, one (9%) had staining in the ipsilateral ACA and MCA territories, eight (73%) had staining in the ipsilateral MCA and bilateral ACA territories, and two (18%) had diffuse staining in all four areas.
Disruption of the BBB in the ipsilateral cerebellar hemisphere was also seen in 25 (51%) of 49 animals with Grade 1 + staining, in 35 (83%) of 42 animals with Grade 2+ staining, and in the one (100%) animal with Grade 3+ cerebral staining. This was irrespective of the agent used to disrupt the BBB.
At Grade 1 + and 2+ staining, the blue discoloration was mottled in character and the density varied markedly within the area of brain, involving both the white and gray regions. Grade 3+ staining was more homogeneous but still had marked variability within any given region in the brain.
Long-Term Survival
Because the future use of transient BBB disruption for therapeutic studies would also require long-term survival, groups of animals were also treated and allowed to survive for 2 weeks. Of 10 animals given 1.4 M intracarotid mannitol at 0.026 ml/sec for 30 seconds, all survived for 2 weeks. Of these, four had had transient respiratory arrests at the time of disruption, only one of which required resuscitation. None of these animals demonstrated any evidence of neurological dysfunction at any time over the 2-week period. Five animals re- ceived 1.4 M mannitol at an infusion rate of 0.052 ml/ sec, and all animals survived for 2 weeks. Of these, all had transient respiratory arrest requiring resuscitation, and for 24 hours following administration one animal appeared to have a mild left hemiparesis which subsequently cleared. Twenty-five animals were given arabinose at 0.026 ml/sec for 30 seconds, and all survived for the 2-week period. Of the 25 animals, 22 (88%) had transient respiratory arrests, and of these, 11 (50%) required resuscitation. None of these animals demonstrated any evidence of focal neurological dysfunction once they had recovered from anesthesia. All 30 animals survived 2 weeks following infusion with 10% DMSO at 0.026 ml/sec for 30 seconds. At 24 hours following infusion, five had a mild hemiparesis which subsequently resolved. Ten animals received 20% DMSO at 0.026 ml/sec for 30 seconds, and nine survived for 2 weeks. Of 35 animals injected at 0.026 ml/sec for 30 seconds with 30% DMSO, five (14%) died within 24 hours of injection, despite attempted resuscitation. The remainder of the animals survived 2 weeks. All of the animals demonstrated generalized epileptiform shaking following administration of DMSO. At 24 hours, all surviving animals had a hemiparesis which cleared by 72 hours.
Discussion
In the present study, successful disruption of the BBB has been obtained in 40-to 99-gin Fischer 344 rats utilizing both mannitol and arabinose. With mannitol, disruption was achieved at flow rates ranging from 0.01 to 0.1 ml/sec for 30 seconds. These flow rates are much less than has previously been reported as necessary in larger animals, 6,~8-2~ which may reflect the degree of maturation of the rat brain in the age range studied. 21 The rat brain shows progressive growth until 4 months of age, with a parallel increase in regional cerebral blood flow and glucose metabolism during that time; this may explain the greater degree of susceptibility to osmotic BBB disruption seen in the immature rat. This is supported by the fact that younger 40-to 69-gm animals had a higher percentage with BBB disruption than did the 70-to 99-gm animals.
While both mannitol and arabinose were satisfactory, arabinose more consistently resulted in BBB disruption at all flow rates evaluated. Arabinose also resulted in a higher percentage of animals having respiratory arrests. However, these arrests were generally transient and frequently did not require resuscitatory efforts, and long-term survival studies did not demonstrate either obvious neurological impairment or subsequent death. Neither 0.9% intracarotid saline nor 1.4 M mannitol administered via the femoral artery resulted in BBB disruption at any flow rate evaluated.
Intravenous DMSO has been shown to alter the BBB to various molecules, including horseradish peroxidase (HRP), possibly by increasing pinocytosis of the endothelial cells 3 or by precipitating seizure activity. 4 However, in contrast to hyperosmolar disruption, delivery of chemotherapeutic agents following this alteration in BBB has been reported to only be marginal. 12' 14 In one of these reports ~4 using adult Sprague-Dawley rats (weighing 250 to 300 gm), DMSO administered intravenously at concentrations ranging from 25% to 90%, given as an intracarotid infusion at 30% at a flow rate of 0.12 ml/sec for 30 seconds, or given by slow intracarotid infusion of 2 ml/10 min, demonstrated only a small increase in brain methotrexate (MTX) or hexosaminidase A levels. With intracarotid high-flow DMSO, MTX levels in the ipsilateral hemisphere were only two to five times higher than in the contralateral hemisphere in three rats evaluated. In these rats, all three animals had seizure activity, one died acutely after infusion, and all had Grade 1 + to 3+ EBD evidence of BBB disruption, all of which closely parallel the results seen in our study. In that report, however, the MTX was infused 2 hours after the administration of DMSO, a time at which BBB disruption might have returned to normal or nearly normal exclusion. When osmotic agents such as 1.6 M arabinose have been used to disrupt the BBB in adult rats, the maximum change in BBB occurs in the first 15 minutes and the majority of the effect is reversed within 2 hours. 2~
In the present study, intracarotid administration of 30% DMSO resulted in a consistently high percentage of animals demonstrating BBB disruption to EBD. However, virtually all of these animals demonstrated immediate seizure activity and severe respiratory arrest. The immediate 8% mortality rate associated with the infusion of 30% DMSO precluded its use for therapeutic evaluation. At lower concentrations, the morbidity and mortality rates were still unacceptably high at 20%, although not at 10% DMSO. At the lower concentration, the percentage of animals with BBB disruption declined to relatively low levels: three (30%) of 10 animals showed disruption at 20% DMSO, and seven (50%) of 14 animals at 10% DMSO.
The goal for animal models is to recreate in the laboratory under experimental conditions a model of brain tumors closely approximating tumors existing in humans. Several of the more widely used animal models, including the ASV-induced glioma and the immune-depressed rat model, employ the Fischer 344 rat and require treatment in animals weighing between 40 and 99 gm. The ASV-induced glioma model is currently the most widely used autochthonous experimental brain-tumor model. It has a glial morphology and heterogeneity similar to human anaplastic .astro-cytomas, 7 the animal host demonstrates a pattern of cell-mediated immunodepression similar to that in humans bearing tumors, 22 the patterns of therapeutic response to radiotherapy and various chemotherapeutic agents appear to resemble those seen in human studies, 26 and, both morphologically and physiologically, its capillary endothelium and BBB are variable, l~ while the immunodepressed rat model has the advantage of using human tumors rather than animal tumors. The small size of rats used in the ASV-induced glioma and the immunodepressed rat models has, however, prevented the design of experiments requiring drug delivery by routes other than oral, intraperitoneal, or intravenous. Until recently, even injections into the carotid artery had not been successfully performed in animals weighing less than 150 gin, and were usually described in animals of more than 300 gm. 5' 15 ' 27 It has been known since before the turn of the century that a functional BBB exists. Anatomically and physiologically this barrier prevents the movement from the blood into the brain of ionic compounds, molecules of large molecular weight, and polar nonelectrolytes. The constitution of this barrier is not entirely known, but anatomically it appears to exist at the tight junction of cerebral capillary endothelia. 19 The BBB has frequently been cited to explain the resistance of brain tumors to systemically administered chemotherapeutic agents. However, in malignant gliomas, discontinuous and fenestrated endothelia are commonly found and blood channels are often lined with tumor cells, z8 Also, among experimental glioma models, an enormous degree of heterogeneity with regard to permeability of HRP both among and within gliomas has been demonstrated.l~ In humans this also appears to be true, and both radionuclide and computerized tomography scans have confirmed an increased and often heterogeneous permeability in human gliomas. 23 The role played by the BBB in resistance of human tumors to drugs is, however, unknown. Because the dose-response curve for most cancers to chemotherapeutic agents is quite steep, and because cellular drug resistance may be dose-related, small increases in drug delivery to tumors may be crucial. Based upon this premise, recent interest has been generated in increasing drug delivery to tumors by either direct intracarotid drug administration or by intracarotid administration following transient BBB disruption. Some clinicaP 7 and experimental studies 15 ' 16 have suggested that osmotic modification of the BBB results in increased drug delivery to tumor tissue. Neuwelt, et al., 15 utilizing a technique originally developed by Rapoport, et al., 19"2~ in adult rats with ASV-induced gliomas, osmotically disrupted the BBB with mannitol and administered intracranial MTX. Measurement of MTX levels at a single time point demonstrated significantly increased delivery of MTX to the tumor-bearing hemisphere, including the tumor, brain around the tumor, and brain distant from the tumor. However, tumor-bearing animals in this study were treated at a much older age than that of rats used for standard therapeutic trials with the ASV model, 25'26 and MTX levels were determined at only a single time point. In contrast, Allen, et al., 1 found that the osmotic disruption of the BBB resulted in a markedly increased drug concentration in the ipsilateral brain distant from the tumor but not in the tumor or in brain adjacent to the tumor with the transplanted Walker 256 carcinoma rat model. Nakagawa, et al.? 3 studying bilateral RG-2 brain tumors in Fischer rats, found no significant increase in the average mean and regional blood-to-tissue transfer constant following unilateral intracarotid perfusion with arabinose. In contrast, the transfer constant for brain tissue adjacent to the tumors and ipsilateral non-tumorous brain regions was increased. In a third transplantable rat brain-tumor model, intracarotid mannitol did not significantly increase capillary permeability of C6 rat gliomas, suggesting that the BBB was already open maximally? ~ The difference in results obtained among studies has not been explained and may reflect the difference between autochthonous versus transplanted brain tumors, between single time point versus transfer constant determination of drug delivery, or other undetermined factors. In none of these studies has an attempt been made to determine if an increase in therapeutic efficacy was associated with the BBB disruption.
Transient BBB disruption may potentially be a valuable method for delivering chemotherapeutic or radiopharmaceutical agents to the central nervous system for the treatment of brain tumors. Its value and limitations, however, need to be further defined in the laboratory setting prior to large-scale or widespread use in humans. The technique described in this paper should allow such work to be performed in a variety of well characterized small-animal brain-tumor models currently in use.
